Alkylating agents

Alkylating agents has been studied in 7 papers since 2016: 5 observational studies in people, 2 reviews; 3 in the past year. The newest story, Nov 12, 2026: “Later Hodgkin lymphoma treatment linked to lower solid cancer risk”.

Intervention

7 papers study it6 findingsUpdated

2 new papers in 30 daysSee all 7 papers on alkylating agents

At a glance

The findings reach people, from one lab or study. 4 independent labs in 4 countries.

“Alkylator use with radiotherapy was associated with reduced risks of breast cancer but increased risks of GI cancers.”
Second Cancer Risk in Female Survivors of Hodgkin Lymphoma: A National Cohort Analysis Across Treatment ErasJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026doi:10.1200/jco-26-00418

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 4 independent labs in 4 countries
  • Funders: National Cancer Institute and others
  • Humans5

What did studies of alkylating agents find?

2

Studies of alkylating agents measured 2 outcomes: clonal hematopoiesis of indeterminate potential and testosterone deficiency.

Clonal hematopoiesis of indeterminate potential

upin humans1

1 study
  1. Alkylating agents increase clonal hematopoiesis of indeterminate potential in humans (pre-existing mutant clones in multiple myeloma).

    “anti-MM therapies such as alkylators and immunomodulatory drugs can favor the expansion of pre-existing mutant clones.”

    Reviewpre-existing mutant clones in multiple myeloma

    Pathogenic and Clinical Implications of the 2-Way Interplay Between Clonal Hematopoiesis of Indeterminate Potential and Multiple Myeloma

    Clinical lymphoma, myeloma & leukemia

More on Clonal hematopoiesis of indeterminate potential

Testosterone deficiency

no changein humans1

1 study
  1. Alkylating agents were not clearly linked with testosterone deficiency in humans.

    “Testosterone deficiency developed typically during pediatric follow-up, and it was associated with testicular radiation ≥20 Gy (HR 41.2, 95%CI 15.4-110) but not with alkylating agents.”

    Humansmalesn = 200

    Influence of therapy exposures on specific late morbidities, prescription drug purchases, and mortality in aging male survivors of childhood cancer: A registry-based study

    International journal of cancer

More on Testosterone deficiency

What is alkylating agents linked with?

4

Studies link alkylating agents with 4 measures, among them gastrointestinal cancer, breast cancer and sarcopenia.

Gastrointestinal cancer

upin humans1

1 study
  1. Alkylating agents are associated with gastrointestinal cancer in humans (Use with radiotherapy in Hodgkin lymphoma survivors).

    “Alkylator use with radiotherapy was associated with reduced risks of breast cancer but increased risks of GI cancers.”

    HumansUse with radiotherapy in Hodgkin lymphoma survivorsfemales

    Later Hodgkin lymphoma treatment linked to lower solid cancer risk

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

More on Gastrointestinal cancer

Breast cancer

downin humans1

1 study
  1. Alkylating agents are associated with breast cancer in humans (Use with radiotherapy in Hodgkin lymphoma survivors).

    “Alkylator use with radiotherapy was associated with reduced risks of breast cancer but increased risks of GI cancers.”

    HumansUse with radiotherapy in Hodgkin lymphoma survivorsfemales

    Later Hodgkin lymphoma treatment linked to lower solid cancer risk

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

More on Breast cancer

Sarcopenia

upin humans1OR 1.34

1 study
  1. Alkylating agents are linked with a higher risk of sarcopenia in humans (adult childhood cancer survivors) (OR 1.34 (95% CI 1.04 to 1.72)).

    “and alkylating agents (OR = 1.34, 95% CI = 1.04 to 1.72) increased”

    Humansadult childhood cancer survivorsn = 1,762

    The Association of Mitochondrial Copy Number With Sarcopenia in Adult Survivors of Childhood Cancer

    Journal of the National Cancer Institute

More on Sarcopenia

p16INK4a

upin humans1

1 study
  1. Alkylating agents are associated with p16INK4a in humans (allogeneic transplant) (p=0.01).

    “prior exposure to alkylating agents (p=0.01)”

    Humansallogeneic transplantT-cells

    Chemotherapy and Stem Cell Transplantation Increase p16INK4a Expression, a Biomarker of T-cell Aging

    EBioMedicine

More on p16INK4a

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 1May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 13 papers in 12 months
Journal of Clinical Oncology

Later Hodgkin lymphoma treatment linked to lower solid cancer risk

Among female Hodgkin lymphoma survivors, treatment in 2000–2010 was associated with a 25% lower relative risk of solid cancers than treatment in 1954–1989.Among female Hodgkin lymphoma survivors, treatment in 2000–2010 was associated with a 25% lower relative risk of solid cancers than treatment in 1954–1989.

Cohort · 7,428 peoplePopulations